Vcanbio Cell & Gene Engineering Corp., Ltd

SHSE:600645 Stock Report

Market Cap: CN¥8.1b

Vcanbio Cell & Gene Engineering Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Vcanbio Cell & Gene Engineering.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth29.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Feb 11

Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • Jan 15

Investor Optimism Abounds Vcanbio Cell & Gene Engineering Corp., Ltd (SHSE:600645) But Growth Is Lacking

With a median price-to-sales (or "P/S") ratio of close to 6.6x in the Biotechs industry in China, you could be forgiven...
Analysis Article • Sep 27

Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Popularity With Investors Is Under Threat From Overpricing

With a median price-to-sales (or "P/S") ratio of close to 5.7x in the Biotechs industry in China, you could be forgiven...
Analysis Article • Aug 26

Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • May 24

Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • May 02

Vcanbio Cell & Gene Engineering's (SHSE:600645) Soft Earnings Are Actually Better Than They Appear

Soft earnings didn't appear to concern Vcanbio Cell & Gene Engineering Corp., Ltd's ( SHSE:600645 ) shareholders over...
Analysis Article • Apr 24

Subdued Growth No Barrier To Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Price

With a price-to-earnings (or "P/E") ratio of 56.9x Vcanbio Cell & Gene Engineering Corp., Ltd ( SHSE:600645 ) may be...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vcanbio Cell & Gene Engineering has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SHSE:600645 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20261,421110249295N/A
12/31/20251,455114264314N/A
9/30/20251,47275279331N/A
6/30/20251,50073260310N/A
3/31/20251,53888252310N/A
12/31/20241,585100218285N/A
9/30/20241,593107209291N/A
6/30/20241,594109198285N/A
3/31/20241,610109205293N/A
12/31/20231,590106210299N/A
9/30/20231,581131179269N/A
6/30/20231,584131170269N/A
3/31/20231,538115159259N/A
12/31/20221,555113163262N/A
9/30/20221,55279157267N/A
6/30/20221,536109185304N/A
3/31/20221,563146165302N/A
12/31/20211,535155193321N/A
9/30/20211,509-69222325N/A
6/30/20211,467-97192282N/A
3/31/20211,409-87217290N/A
12/31/20201,319-127153244N/A
9/30/20201,3518993236N/A
6/30/20201,33868102233N/A
3/31/20201,34225118240N/A
12/31/20191,38750N/A241N/A
9/30/20191,355-182N/A234N/A
6/30/20191,345-189N/A183N/A
3/31/20191,320-43N/A135N/A
12/31/20181,32159N/A130N/A
9/30/20181,333317N/A83N/A
6/30/20181,327322N/A165N/A
3/31/20181,434116N/A141N/A
12/31/20171,32110N/A104N/A
9/30/20171,23860N/A127N/A
6/30/20171,11322N/A46N/A
3/31/201787672N/A128N/A
12/31/201683838N/A144N/A
9/30/2016768130N/A85N/A
6/30/2016740-64N/A37N/A
3/31/201672141N/A-17N/A
12/31/2015709208N/A8N/A
9/30/201567669N/A134N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 600645's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if 600645's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 600645's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 600645's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 600645's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 600645's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/17 15:42
End of Day Share Price 2026/07/17 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vcanbio Cell & Gene Engineering Corp., Ltd is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ye Hui YangHuatai Research
Ban WangMinsheng Securities Co.
Tao FuTopsperity Securities